CAR-T cell therapy: from assessment to infusion and follow-up
CAR-T therapy uses immune cells engineered to recognize a particular target on cancer cells. For a patient, the treatment includes several linked stages: checking eligibility, collecting cells, preparing for infusion and arranging close follow-up. Understanding the whole sequence helps you plan treatment and travel.
On this page
How CAR-T cells recognize cancer
T cells are part of the immune system. In an autologous CAR-T treatment, a laboratory modifies a patient's own T cells to carry a chimeric antigen receptor, or CAR. This receptor helps them recognize a selected protein on cancer cells. The cells can then expand after they are returned to the patient.
The target and the product matter. CD19-directed products are used in certain B-cell cancers, while BCMA-directed products are used in multiple myeloma. Each has defined treatment settings. The diagnosis and previous medicines are therefore the starting point for an assessment.
Sources and references: [1]
Find out which pathway fits the diagnosis
CAR-T has established uses in several blood cancers, including selected leukemias, lymphomas and myeloma. In China, satri-cel also received approval in June 2026 for CLDN18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma after at least two prior lines have failed. Other solid-tumor uses require their own assessment of approved options or trials.
Ask for the proposed product name and the reason it fits your disease. A useful explanation connects the cancer's target, the treatment history and the expected benefit. It should also identify other realistic options for this point in your care.
The team checks readiness before collection
Assessment usually brings together pathology, recent scans or marrow tests, the treatment timeline and an evaluation of your general health. The team looks for infection and reviews organ function, blood counts and medicines that may affect treatment. It also considers whether the disease can remain controlled during preparation.
This is a good time to raise practical needs. Discuss your caregiver, accommodation, language support and access to urgent care. Ask which appointments require you to be present and what records can be reviewed in advance, particularly if you are coming from another country.
Cell collection is a separate appointment
During leukapheresis, blood passes through a machine that collects the cells needed for manufacturing, while other blood components are returned. The team checks whether the veins are suitable or another form of access is needed. It will also give instructions about medicines and preparation.
After collection, the cells are sent for manufacture and quality checks. Ask when the center expects an update and what could change the schedule. Keep the collection date and the product name in your records so that each stage can be coordinated accurately.
Control the cancer while the cells are prepared
Manufacturing commonly takes several weeks, with the actual interval depending on the product and treatment center. Some patients need bridging treatment to control the cancer during this period. The choice depends on the disease, earlier response and the timing of collection and infusion.
Ask how the team will monitor you while waiting and what symptoms should prompt a call. Also ask what the next plan would be if the cancer progresses, an infection develops or the manufactured cells are not ready on the expected date. These answers make the waiting period easier to manage.
Preparing the body and receiving the cells
Before infusion, many CAR-T regimens use a short course of lymphodepleting chemotherapy. This reduces some existing immune cells and helps create conditions in which the CAR-T cells can expand. The team reassesses your health before proceeding and explains how to manage this part of treatment.
The cells are then infused through a vein according to the product's schedule. The infusion appointment is only one part of the course. Ask what monitoring begins immediately afterward and whether your treatment will involve inpatient care, closely supervised outpatient care or a combination.
Close observation continues after infusion
The team watches for cytokine release syndrome, or CRS, and neurological effects such as confusion or difficulty speaking. Infection and low blood counts also need attention. Fever, breathing difficulty, marked drowsiness or a new neurological change require prompt contact with the treating team, with emergency care for severe symptoms.
Monitoring requirements vary by product and local practice. Get written instructions about staying near the center, caregiver support, driving and follow-up tests. Later visits assess both the cancer response and recovery of blood counts and immune function.
Start a Shanghai assessment with the treatment history
EastMedGo can help organize an initial CAR-T eligibility assessment and clarify which documents the receiving team needs. Shanghai hematology resources include Ruijin Hospital; the appropriate center depends on the disease, proposed product and current service arrangements.
When you contact EastMedGo, include the exact diagnosis, previous treatment names, latest response and the decision you are facing. We can coordinate record preparation and appointment requests, then help clarify the expected sequence of visits, local stay and follow-up once the hospital has reviewed the case.
Sources and references: [6]
Common questions
Is CAR-T a single treatment visit?
Cell infusion is one stage. Assessment, collection, manufacturing, preparatory treatment and follow-up require additional time and visits. Ask for a schedule covering the whole course, including possible changes.
Will I need chemotherapy before CAR-T?
Many CAR-T regimens use lymphodepleting chemotherapy shortly before infusion. Some patients also need bridging treatment while cells are being prepared. The purpose and timing of each should be explained separately.
When should an overseas patient arrange travel?
Begin with a record review and confirm which assessment must happen in person. Ask the hospital to clarify collection, product preparation and monitoring arrangements before fixing a return date.
Sources and references
- CAR T Cells: Engineering Immune Cells to Treat Cancer
- 国家药监局批准舒瑞基奥仑赛注射液上市
- T-cell Transfer Therapy
- ABECMA (idecabtagene vicleucel): prescribing information
- FDA Eliminates Risk Evaluation and Mitigation Strategies (REMS) for Autologous Chimeric Antigen Receptor CAR T cell Immunotherapies
- Ruijin Hospital
Prepared with AI assistance by EastMedGo for patients comparing treatment and care options.